ID   SW954
AC   CVCL_1732
SY   SW-954; SW 954
DR   CLO; CLO_0009204
DR   EFO; EFO_0002376
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-117
DR   BioSample; SAMN03471097
DR   CCLE; SW954_VULVA
DR   Cell_Model_Passport; SIDM01157
DR   ChEMBL-Cells; CHEMBL3307461
DR   ChEMBL-Targets; CHEMBL614943
DR   Cosmic; 924247
DR   Cosmic-CLP; 924247
DR   DepMap; ACH-001400
DR   GDSC; 924247
DR   GEO; GSM1670517
DR   IARC_TP53; 27255
DR   IGRhCellID; SW954
DR   LINCS_LDP; LCL-1295
DR   PharmacoDB; SW954_1550_2019
DR   Wikidata; Q54971219
RX   PubMed=924690;
RX   PubMed=3518877;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   From: Scott and White Clinic; Temple; USA.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Homozygous for TP53 p.Arg158His (c.473G>A) (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.24%; Native American=0%; East Asian, North=0.14%; East Asian, South=0.57%; South Asian=1.33%; European, North=70.36%; European, South=27.38% (PubMed=30894373).
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9,11
ST   D16S539: 11
ST   D5S818: 11,12
ST   D7S820: 11,13
ST   TH01: 8,9.3
ST   TPOX: 8
ST   vWA: 14,15
DI   NCIt; C4052; Vulvar squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   86Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-19; Version: 24
//
RX   PubMed=924690; DOI=10.1002/ijc.2910200505;
RA   Kerbel R.S., Pross H.F., Leibovitz A.;
RT   "Analysis of established human carcinoma cell lines for
RT   lymphoreticular-associated membrane receptors.";
RL   Int. J. Cancer 20:673-679(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//